tiprankstipranks
BeiGene presents new analyses for BRUKINSA
PremiumThe FlyBeiGene presents new analyses for BRUKINSA
1M ago
BeiGene treatment of membranous nephropathy granted orphan designation
PremiumThe Fly
BeiGene treatment of membranous nephropathy granted orphan designation
1M ago
BeiGene initiated with a Buy at Bocom
PremiumThe Fly
BeiGene initiated with a Buy at Bocom
2M ago
BeiGene receives European Commission approval for tislelizumab
PremiumThe FlyBeiGene receives European Commission approval for tislelizumab
2M ago
Drugmakers look to alternative suppliers after draft U.S. legislation, FT says
PremiumThe Fly
Drugmakers look to alternative suppliers after draft U.S. legislation, FT says
3M ago
BeiGene price target lowered to $164.30 from $179.30 at BofA
PremiumThe Fly
BeiGene price target lowered to $164.30 from $179.30 at BofA
3M ago
BeiGene receives FDA approval for Tevimbra
PremiumThe FlyBeiGene receives FDA approval for Tevimbra
4M ago
BeiGene gets approval for Tevimbra BLA
PremiumThe Fly
BeiGene gets approval for Tevimbra BLA
4M ago
BeiGene announces first doses of Brukinsa administered
PremiumThe Fly
BeiGene announces first doses of Brukinsa administered
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100